Faeth Therapeutics to Present at Raymond James Biotech Private Company Showcase
2024年7月17日 - 9:01PM
ビジネスワイヤ(英語)
Faeth Therapeutics (Faeth), a clinical-stage biotechnology
company, announced that Oliver Maddocks, Co-Founder and Chief
Scientific Officer, and Debbie Chirnomas, M.D., Chief Medical
Officer, will present today at the Raymond James Biotech Private
Company Showcase. Oliver and Debbie will discuss Faeth’s lead
PIKTOR program development plans and participate in a Q&A
following the presentation.
Faeth's lead program, FTH-001/003 or "PIKTOR," features the
combination of serabelisib, a PI3Kɑ inhibitor, and sapanisertib, an
mTORC 1/2 inhibitor. This combination effectively targets and shuts
down the PI3K pathway, one of the most frequently mutated pathways
in cancer. PIKTOR has demonstrated impressive outcomes in a Phase
1b trial across endometrial, ovarian, and breast cancers in
conjunction with paclitaxel. Additionally, Faeth's second clinical
initiative involves FTH-002, a specially designed amino acid sachet
administered alongside an amino acid-restricted diet and
radio/chemotherapy.
Faeth boasts a strong clinical and preclinical pipeline, fueled
by its MetabOS discovery platform. This platform utilizes AI,
machine learning, and carefully selected data sets to pinpoint
targets tailored to specific tumor genotypes.
Established by luminary oncology researchers including Drs. Lew
Cantley, Siddhartha Mukherjee, and Karen Vousden, Faeth is
dedicated to developing therapies that target cancer metabolism.
While the significance of metabolism in cancer growth is
recognized, it is still largely underutilized in treatment, with
only a handful of therapies available. Faeth employs a unique
strategy that combines an in-depth understanding of cancer
metabolism, functional genomics, and computational biology to
create effective, less toxic treatments.
About Faeth Therapeutics
Faeth Therapeutics is a clinical-stage biotechnology company at
the forefront of oncology research with a robust clinical and
preclinical pipeline powered by its AI-driven MetabOS discovery
platform. Faeth’s lead program, PIKTOR, has shown outstanding
clinical results in a Phase 1b trial and is advancing into a Phase
2 trial in endometrial cancer in 2024. For additional information,
visit www.faeththerapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717288408/en/
Media Contact Patrick Schmidt 630-290-2787
faeththerapeutics@consortpartners.com